Healthcare · Profile from Healthcare Research Companion
Clover Health Investments, Corp.
The venture-backed "insurtech" Medicare Advantage plan that promised to beat incumbents with data science and a physician software tool, raised over $900m privately, went public through Chamath Palihapitiya's SPAC at a ~$3.7bn valuation, was hit within a month by a short-seller report and federal inquiries, lost more than $1bn over 2021–2023, retreated from its Medicare experiment (ACO REACH), and then rebuilt itself around a wide-network PPO, its Clover Assistant software (sold externally as Counterpart Assistant) and, in 2026, a court fight over its star ratings and a first expected year of GAAP profit.
At a glance
- Founded
- 2014 (CEO tenure of co-founder Vivek Garipalli dates from July 2014); early operations in New Jersey and San Francisco
- Founders
- Vivek Garipalli (CEO 2014–2022, previously founder of the CarePoint Health hospital group in Hudson County, New Jersey) and Kris Gale (CTO, formerly of Yammer; left ~2017, reported)
- Headquarters
- Franklin, Tennessee (corporate address in filings); large operations in New Jersey
- Ownership / structure
- Public company, Nasdaq: CLOV since January 2021 via merger with Social Capital Hedosophia Holdings Corp. III (IPOC); dual-class shares (Class B high-vote shares held mainly by Garipalli)
- Leadership (2026)
- Andrew Toy, CEO (since January 1, 2023); Vivek Garipalli, executive chair; Clay Thornton, interim CFO (2026, reported); Counterpart Health run as a subsidiary (verify current titles)
- Segment and buyer
- Payer (Medicare Advantage, mainly a wide-network PPO) plus health IT / physician enablement (Counterpart Health); the buyer is the federal government via CMS capitation, the member choosing the plan, and external payers and provider groups licensing software
- Scale
- ~113,800 MA members at end-2025 (+38%) and ~157,300 at June 30, 2026 (+48% y/y, reported); 2025 total revenue $1,924.3m (+40%); 2025 GAAP net loss $85.5m; Q2 2026 GAAP net income $28.0m
- Capital raised / valuation / market cap
- ~$925m raised privately 2014–2019 (Greenoaks-led rounds; ~$1.2bn valuation reported in 2017); SPAC merger at ~$3.7bn pro forma equity value with ~$1.2bn gross proceeds incl. a ~$400m PIPE (reported); shares fell below $1 in 2023 and recovered to the low-to-mid single digits in 2024–2026 (verify)
- Signature moves (incl. failures)
- Data-first MA plan in New Jersey; Greenoaks mega-rounds; Clover Assistant; 2021 SPAC; Hindenburg report, SEC and DOJ inquiries and a $22m class settlement; Direct Contracting/ACO REACH bet and exit; 2023 CEO handover and cost reset; Counterpart Health SaaS spin-out (2024); 2025 growth surge with cost spike; 2026 star-ratings lawsuit win (under appeal) and turn to profit
9 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2014
Founding Data Driven MA Plan
Founding
2016
Greenoaks Mega Rounds
Funding round (series of late-stage private rounds)
2018
Clover Assistant Platform
Launch / AI launch (clinical decision support for physicians)
2021
Direct Contracting ACO REACH
Launch (entry into CMS Global and Professional Direct Contracting) and later exit (divestiture of line of business)
2021
Hindenburg Report and Investigations
Regulatory settlement (crisis response, investigations and litigation)
2021
SPAC Merger Social Capital
SPAC
2023
CEO Change and Cost Reset
Restructuring (leadership succession, workforce reduction, operations outsourcing)
2024
Counterpart Health Launch
Spin-off (internal subsidiary) / AI launch
2026
Star Ratings Lawsuit and Profitability
Regulatory challenge (litigation against CMS) and strategy (growth then margin recovery)